Fast-Track Your Antibody Drug Conjugate

Simtra BioPharma Solutions is a trusted partner for developing complex Antibody Drug Conjugate (ADC) therapies, which are becoming the future standard of cancer treatment. The company offers over 10 years of experience in manufacturing ADC programs , having successfully transferred more than 60 ADC programs, including six commercial ADCs.

Simtra provides clinical and commercial manufacturing services with expertise in Oncology and ADCs. Their facilities are SafeBridge Certified and equipped to handle OEB 5 chemicals. Significant investments are underway, including a $100M expansion in Halle/Westfallen, Germany, to boost commercial ADC capacity by early 2026 , and an additional $14M investment to expand ADC conjugation and purification capabilities. The facility supports conjugation, purification, and fill/finish services from early development through commercial production. Discover the full range of development, pre-commercial, fill/finish, and conjugation capabilities available to accelerate your ADC program.